Data Sheet (Cat.No.TMAY-03780)

TargetMol

Anti-CEACAM1 Antibody (9M305)

Product Details

Ig Type:	Mouse IgG1
Reactivity:	Rat
Conjugation:	Unconjugated
Clone:	9M305
Purification:	Protein A

Applications

Verified Activity:	Flow cytometric analysis of Rat CEACAM1(CD66a) expression on SD rat splenocytes. Cells were stained with purified anti-Rat CEACAM1(CD66a), then a FITC-conjugated second step antibody. The fluorescence histograms were derived from gated events with the forward and side light-scatter characteristics of intact cells.
Application:	FCM
Recommended	FCM: 1:25-1:100

Properties

Stability & Storage:	Store at 2°C-8°C for 1 month. Store at -20°C or -80°C for 12 months. Avoid repeated freeze-thaw cycles. Preservative-Free.
Shipping:	Shipping with blue ice.

Antigen Details

Immunogen:	Recombinant Protein: Rat CEACAM-1/CD66a Protein (TMPY-03240)
Antigen Species:	Rat
Synonyms:	carcinoembryonic antigen-related cell adhesion molecule 1 (biliary glycoprotein);BGP;CD66a;BGP1;CEACAM-1;BGPI
Biology Area:	Cancer Drug Targets, ITIM/ITAM Immunoreceptors and Related Molecules

Research Background

The carcinoembryonic-antigen-related cell-adhesion molecule (CEACAM) family of proteins has been implicated in various intercellular-adhesion and intracellular-signalling-mediated effects that govern the growth and differentiation of normal and cancerous cells. CEACAM1, also known as biliary glycoprotein I (BGP I) and CD66a, is a member of the carcinoembryonic antigen (CEA) gene family which belongs to the immunoglobulin superfamily. The highly glycosylated CEACAM1 contains one N-terminal V-type Ig-like domain and three C2-type Ig-like domains within its ECD, and one ITIM motif and a calmodulin binding site in the cytoplasmic region. CEACAM1 is a surface glycoprotein expressed on various blood cells, epithelial cells, and vascular cells. It was described as an adhesion molecule mediating cell adhesion via both homophilic and heterophilic manners, and was detected on leukocytes, epithelia, and endothelia. Studies have revealed that CEACAM1 performs actions in multiple cellular processes including tissue differentiation, angiogenesis, apoptosis, metastasis, as well as the modulation of innate and adaptive immune responses.Cancer ImmunotherapyCo-inhibitory Immune Checkpoint TargetsImmune CheckpointImmune Checkpoint Detection: ELISA AntibodiesImmune Checkpoint Detection: FCM AntibodiesImmune Checkpoint Detection: ICC AntibodiesImmune Checkpoint Detection: IHC AntibodiesImmune Checkpoint Detection:

WB AntibodiesImmune Checkpoint ProteinsImmune Checkpoint TargetsImmunotherapyTargeted Therapy

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481